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The vascular effects of endogenous substances can be 
easily studied in the skin. Early in this century, 
vasoregulation was shown to be dependent on inner­
vation. Peptidergic transmitters have been shown to 
co-exist and co-transmit along with noradrenalin and 
acetylcholine, sometimes being responsible for non­
adrenergic-noncholinergic responses. This review 
summarizes recent information on vasoregulatory 
effects of neuropeptides such as substance P (SP), 
neurokinin A (NKA), calcitonin gene-related peptide 
(CGRP), vasoactive intestinal peptide (VIP), pituitary 
adenylate cyclase activating peptide (PACAP), neu­
ropeptide Y (NPY), and somatostatin. All these pep­
tides are vasodilators, and some of them seem to be 
involved in neurogenic inflammation. Some vasoac­
tive peptides and other vasoactive molecules, such as 
nitric oxide (NO) and histamine, can originate both 
T he skin protects the body from noxious agents in the environment. Nerve fibers in the skin provide the chemical mediators that enable blood vessels and other structures to respond to external stimuli. In 1901 Bayliss showed that stimulation of primary 
alferent nerve fibers will evoke vasodilatation in the skin. The term 
'axon reflex' was introduced to describe the conjunction of alferent 
(orthodromic) and elferent (anti-dromic) conduction of impulses 
(Bayliss, 1901). The alferent function of sensory nerves is to signal 
the presence of nociceptive stimuli to the central nervous system, 
where they will be interpreted as pain, itch, etc. Their elferent 
function is to contribute to the local defense against harnlful 
(nociceptive) stimuli. Neuropeptides are involved in both these 
functions (Lembeck and Holzer, 1979). 
The skin is also supplied with parasympathetic and sympathetic 
nerve fibers. Blood vessels and sweat glands are regulated by 
sympathetic fibers. Most post-ganglionic sympathetic nerves release 
noradrenaline (NA) , which may act on either a- or f3-adrenore­
ceptors. The sympathetic fibers that supply sweat glands are 
cholinergic. Parasympathetic stimulation has little elfect on blood 
vessels, except in certain restricted areas such as the blush area of 
the face and neck. In many organ systems, autonomic nervous 
transmission cannot be completely blocked by drugs that abolish 
responses to acetylcholine or noradrenaline. The term nonadren­
ergic noncholinergic transmission was coined to denote the in­
volvement of additional chemical mediators. Sensory neurons and 
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from nerves and cells and are crucially involved in 
vasoregulation. Other cell-derived peptides and mol­
ecules, such as bradykinin, endothelins, and prosta­
glandins, may contribute to neurogenic inflamma­
tion. All the peptides and molecules described also 
exist in other organs such as the brain, heart, lung, 
pancreas, and gastrointestinal tract. The effect of 
neuropeptides seems to vary from one organ or tissue 
to another, e.g., NPY is a potent vasoconstrictor in 
cardiac and cerebral vascular beds but acts as a 
vasodilator when it occurs in the skin. The presence 
of mast cells and inflammatory cells may create a 
special environment in the skin. Key words: neuropep­
tideslneurotransmittel'slhistaminelpl'ostaglandin. Journal of 
Investigative Del'matology Symposium Proceedings 2:49-55, 
1997 
nerve fibers form another important part of the peripheral nervous 
system. The axon reflex in human skin depends on the release of 
neuropeptides from sensory C-fibers and on the mobilization of 
histamine from nerve-associated mast cells (Foreman and Jordan, 
1983). Among the neuropeptides that occur in sensory nerve 
endings are substance P (SP) and calcitonin gene-related peptide 
(CGRP). Other agents, such as the peptide bradykinin, which is 
derived from plasma proteins, and prostaglandins, which originate 
from tissue cells, are known to cause or enhance the axon reflex 
owing to their ability to excite or sensitize C-fibers. There is much 
evidence to suggest that additional factors released from vascular 
endothelial cells, such as endothelin and nitric oxide (NO), may act 
as vasoactive mediators. Endothelin is a very potent vasoconstrictor 
peptide, whereas NO is a vasodilator. 
Data accumulated during the past decade suggest that neurons 
release more than one transmitter (i.e., co-transmission) (Burn­
stock, 1987). Thus, NA has been shown to co-exist with neuropep­
tide Y (NPY) in sympathetic nerve terminals. Such co-existence 
has also been shown for acetylcholine and vasoactive intestinal 
peptide (VIP) in parasympathetic nerve fibers. What can co­
transmission achieve that cannot be achieved with a single trans­
mitter? One possibility is that the two mediators operate dilferently, 
one participating in processes that occur within milliseconds, and 
the oilier in slower processes. Another possibility is that the ratio of 
the two mediators released may vary, for instance, with the 
stimulation frequency. This is the case with NA and NPY at 
sympathetic nerve terminals, the release of NPY being less than 
that of NA at low stimulus frequencies but increasing with increas­
ing frequency (Stjarne, 1989). A third possibility is that one of the 
co-existing mediators (e.g., the peptide) may be removed or 
inactivated more slowly than the other (e.g., acetylcholine or NA), 
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Figure 1. Flare responses to SP (50 pmol) in different regions of the 
skin. The degree of response is expressed as the area (cm2), (n = 7, medical 
students aged 24-28 y). 
thus reaching targets further away from the site of release and 
producing more long-lasting effects. 
The aim of this review is to provide an updated comprehensive 
analysis of the effects and mechanisms of action of various vasoac­
tive peptides and other vasoactive molecules in the skin. These 
substances elicit a wide range of responses in many types of cells 
including neurons, smooth muscle, vascular endothelium, exocrine 
gland cells, mast cells, and cells of the immune system. The 
classification into nerve-derived and cell-derived messengers is not 
JID SYMPOSIUM PROCEEDINGS 
Figure 3. Erythema with induration and pseudopodia 2 h after 
intracutaneous injection of 13 pmol CGRP . 
strict, as some molecules such as nitric oxide (NO) and histamine 
can originate both from cellular and neural structures, whereas 
tachykinins, mainly originating from neurons of the dorsal root 
ganglia, may be synthesized in non-neural structures such as 
endothelial cells (Linnick and Moskowitz, 1989), eosinophils, and 
macrophages (Weinstock and Blum, 1990). 
NER VE-DERlVED VASOACTIVE PEPTIDES 
Regulatory peptides normally consist of five to 40 amino acid 
residues, and the peptide precursors are produced in the nerve cell 
bodies. The precursor protein is packaged into granules/vesicles in 
the Golgi area, and the active peptide is generated through 
proteolysis in the secretory organelle, being ready for release by the 
Vasodilatation Vasoconstriction 
Figure 4. Hypothetical scheme of inter­
action between different vasoactive sub­
stances: acetylcholine (Ach), bradykinin 
(BK), calcitonin gene-related peptide 
(CGRP), endothelin (ET), histamine (H); 
neurokinin A (NKA), neuropeptide Y 
(NPY), nitric oxide (NO), noradrenaline 
(NA), prostaglandins (PGE2 and PGI2), 
serotonin (SER), somatostatin (SOM), 
substance P (SP). 
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Figure 2. Flare and wheal reactions in response to SP (AID). NKA 
(BIE) and histamine (elF). Observations in nonnal skin, skin pre-treated 
with compound 48/80, and lidocaine after 5 min (flare) and 15 min (wheal), 
(n = 5-9). Error bars inrlicate mean + SEM. Flare evoked by histamine, SP, 
ar NKA and SP-evoked wheal were significantly reduced (p < 0.01; 
Student's t test for pooled data), whereas wheal evoked by histamine or 
NKA was not significantly reduced. 
time it reaches the nerve terminal. Upon release, the peptide is 
rapidly inactivated through hydrolysis by exo- and endopeptidases. 
The properties of neuropeptides as neurotransmitters and as 
mediators of neurogenic inflammation will be discussed in this 
paper. Other aspects, including neuropeptide-evoked modulation 
of immune responses and tissue proliferation, will be discussed 
elsewere in this issue. 
The Tachykinins (Substance P and Neurokinin A) Sub­
stance P (SP) was first discovered by von Euler and Gaddum in 
1931 and its structure of 11 amino acids was published in 1970. SP 
is encoded by the same gene as neurokinin A (NKA) , which 
consists of ten amino acid residues. Differential splicing of the RNA 
transcript results in the production of two mRNAs and two 
precursor proteins, one of which includes both peptides and the 
other includes SP only. How the splicing process is controlled is not 
well understood, but it is clearly an important regulatory mecha­
nism. Tachykinin receptors are of three subtypes: NK1, NK2, and 
NK3 receptors (Maggi et ai, 1993). Although each tachykinin has 
some affinity for all three receptor subtypes, SP mainly activates the 
NKl receptor. 
SP was put forward as a putative neurotransmitter in sensory 
nerves after the finding of large amounts of SP in the dorsal horn of 
the spinal cord (Lembeck et ai, 1979). The distribution of SP has 
been established using immunochemistry and immunocytochemis­
try. SP is present in primary sensory nerves that have their cell 
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bodies in the spinal and trigeminal ganglia (Sundler et ai, 1985). SP 
has strong vasoactive effects causing vasodilatation and profound 
hypotension. 
SP is thought to be involved as a mediator in sensory processes of 
various types, including nociception and inflammation (Lynn, 
1992). In the skin, SP-immunoreactive nerve fibers are distributed 
as single scattered fibers just beneath the epithelium or penetrating 
into it. They sometimes occur as bundles of fibers in the deeper 
layers and sometimes as single fibers rull1ing either close to blood 
vessels or freely in the connective tissue. Generally, SP fibers are 
few or moderate in number except, for instance, in the skin of 
fingertips where they are numerous and sometimes ramify within 
the corpuscules of Meissner in the papillae. SP-containing nerve 
fibers are also known to form a network around sweat glands and 
blood vessels. Simultaneous demonstration of CGRP and SP has 
revealed their co-existence in spinal nerve cell bodies and in a 
population of subepithelial nerve fibers (Wallengren et ai, 1987). 
Intradermal injection of SP produces flare, wheal, and itch 
(Hagern1ark et ai, 1978). There is regional variation in the flare 
response, which is most prominent on the thorax and less at more 
distal locations, whereas wheal is most manifest on the upper aspect 
of the foot and on the flexor surface of the upper arm (Fig 1) 
(Wallengren et aI, 1992). The itch is most intense on the foot and 
the nape of the neck, indicating that the itch does not correlate to 
the flare response (Wallengren et ai, 1992). The flare response 
diminishes with increasing age and in conditions of physical stress, 
and its magnitude varies with the time of day, being greater at 
night, whereas the wheal response appears to be independent of 
circadian rhythm (Wallengren et ai, 1992). 
SP is known to release mast-cell histamine ill vitro. The depletion 
of histamine from dermal mast cells by compound 48/80 greatly 
reduces the flare response to SP (Foreman and Jordan, 1983), 
suggesting that the flare is dependent upon histamine (Fig 2A). It 
has therefore been postulated that, during the axon reflex, mobi­
lized SP does not evoke vasodilatation directly but through the 
release of mast-cell histamine (Foreman and Jordan, 1983). More­
over, SP-evoked flare is dependent upon an axon reflex, because 
pre-treatment of the skin with lidocaine greatly diminishes the 
response (Foreman and Jordan, 1983) (Fig 2A). Conceivably, 
exogenous SP releases histamine, which in turn stimulates sensory 
nerve fibers to release tachykinins and CGRP. The end result 
reflects the combined direct vascular effects of histamine, tachyki­
nins, and other bioactive agents released from mast cells and 
sensory nerve fibers. The SP-evoked wheal, on the other hand, is 
only moderately affected by pre-treatment with compound 48/80 
and local anestheetics (Fig 2D). Thus, the wheal response seems to 
be largely due to a direct local effect of the injected SP (Foreman et 
al,1983). 
NKA, first isolated from the porcine spinal cord (Kimura and 
Kangawa, 1983), was later shown to activate NK2 receptors (Maggi 
et ai, 1993). It was found to co-exist with SP in primary sensory 
neurons. Like SP, NKA is also active with regard to gall bladder 
contraction, protein extravasation, hypotension, and bronchial 
smooth muscle spasm (Tatemoto et ai, 1985). NKA is less potent 
than SP in inducing flare and itch in human skin. The poor itch and 
flare response to NKA may reflect its weak histamine-releasing 
ability. Nonetheless, the flare evoked by NKA is reduced by 
pre-treatment with compound 48/80 (by about 50%) and is virtu­
ally abolished by the local anesthetic lidocaine (Fig 2B) (Wallen­
gren and Hakanson, 1987). It is therefore conceivable that, like SP, 
NKA acts via sensory fibers and mast cells. The wheal-inducing 
capacity of NKA is similar to that of SP (Fig 2B), although SP is 
more effective in inducing flare (Wallengren and Hakanson, 1987). 
SP, NKA, and CGRP are thought to be released concomitantly 
from sensory nerve fibers in response to physical or chemical 
irritation. It appears that SP effectively mobilizes histamine from 
local mast cells. The histamine released will excite sensory nerve 
fibers causing the release of more SP (together with NKA and 
CGRP) , and tills positive feedback mechanism continues to be 
operative, possibly until all ramifications of the nerve have become 
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engaged in axon reflexes and until available pools of the neuropep­
tides have been exhausted. 
CGRP CGRP, a 37-amino acid peptide, is encoded by the same 
gene that codes for calcitonin and was discovered by Amara and 
colleagues in 1982. Differential splicing allows cells to produce 
either pro-calcitonin (expressed in thyroid C-cells) and/or pro­
CGRP (expressed in many neurons and in thyroid C-cells) from the 
same gene. 
The CGRP receptors have not yet been cloned. There IS 
pharmacologic evidence, however, supporting the existence of 
several receptors (for review see Poyner, 1995). 
CGRP has been found in sensory neurons in the trigeminal 
ganglion and in the spinal ganglia. It co-exists with SP and NKA in 
sensory nerve cell bodies (Sundler et aI, 1985). CGRP is the most 
abundant of all neuropeptides in human skin and is often found to 
be co-localized with SP (Wallengren et aI, 1987). In the skin, 
CGRP-immunoreactive nerve fibres are distributed as single scat­
tered fibers just beneath and sometimes penetrating into the 
epithelium. Occasionally CGRP-positive nerve fibers form fiber 
bundles in the deeper layers, whereas single fibers run either close 
to blood vessels or around sweat glands. The density of CGRP-IR 
fibers is generally moderate, although it is quite high in the skin of 
fingertips, particularly in the papillae. Based on the abundance of 
CGRP-containing fibers, we propose that CGRP is an important 
messenger molecule in the sensory nervous system. In human skin, 
CGRP induces slowly developing local reddening (duration of 
several hours) (Wallengren and Hakanson, 1987) (Fig 3). The 
CGRP-evoked erythema does not seem to be mediated by mast­
cell histamine or by C-fiber tachykinins, as it is not suppressed by 
pre-treatment with mepyramine or compound 48/80 or by lido­
caine treatment. The long-lasting and widespread vascular effects of 
CGRP may reflect a gradual diffusion of the peptide, which 
conceivably exerts direct effects on blood vessels. Although SP and 
CGRP may be released concomitantly from the same C-fibers, they 
seem to differ from each other in their duration of action, CGRP 
being more long-acting. In the immediate phase of inflammation, it 
is likely that SP and histamine, by inducing triple response, play 
crucial parts. The CGRP-evoked erythema continues to develop as 
the effects of SP and histamine subside. Hence CGRP may be 
expected to play a greater part in subsequent stages of inflamma­
tion. Clinical inflammatory reactions are usually more prolonged 
than the rapidly developing flare and wheal reactions, which can be 
induced experimentally, and hence resemble the action of CGRP 
more than that of SP. When injected concomitantly, SP is found to 
shorten the duration of the reddening induced by CGRP (Brain and 
Williams, 1988). NKA does not shorten the duration of the CGRP 
response. Local elimination of mast cells in the skin by treatment 
with compound 48/80 causes SP to lose its ability to shorten the 
duration of CGRP-evoked erythema. These observations suggest 
that an SP-evoked release of proteolytic enzymes from mast cells 
may result in accelerated degradation of CGRP (Brain and Wil­
liams, 1988). 
VIP VIP was isolated from porcine intestine by Said and Mutt in 
1970 and structurally characterized by the same authors 4 y later 
(Mutt and Said, 1974). VIP consists of 28 amino acids and belongs 
to the same family of neuropeptides as secretin and glucagon. 
Recent reports have identified two distinct VIP receptors, VIP 1 and 
VIP 2' which are members of a family of G-protein-linked receptors 
(for a review see Harmar and Lutz, 1994). 
VIP has received its name because of its hypotensive actions and 
because of its potent vasodilatory activity in the splanchnic, coro­
nary, and pulmonary vascular beds where it is present in nerve 
structures (Said and Mutt, 1970). VIP and acetylcholine co-exist in 
post-ganglionic parasympathetic nerve fibers. In the skin, VIP­
containing nerve fibers are distributed preferentially in the deeper 
parts of the dermis in perivascular nerve fibers (Wallengren et aI, 
1987). In eccrine sweat glands, VIP-containing fibers seem to 
innervate glandular cells (Hartschuh et aI, 1983). VIP relaxes the 
smooth muscle of blood vessels and has been suggested to be 
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involved in the regulation of vasodilatation and sweat gland 
function. The amount of VIP in skin varies from one region to 
another, the richest supply occurring in perioral and digital skin. 
VIP induces histamine-dependent flare and wheal when injected 
intradermally (Fjellner and Hagermark, 1981). VIP is found at high 
concentrations in fluid from spontaneous blisters in inflamed skin 
(Wallengren ef ai, 1987). 
Pituitary Adenylate Cyclase-Activating Peptide (PACAP) 
PACAP was discovered in 1989 and consists of two forms, one with 
38 amino acid residues, the other with 27. Both peptides arise from 
a common precursor and belong to the same family as VIP (for 
review see Warren et ai, 1992). Although several receptors that 
interact with both PACAP and VIP have been described, the 
PACAP type I receptor seems to be highly specific for PACAP (for 
review see Harmar and Lutz, 1994). 
PACAP is a powerful activator of adenylate cyclase and seems to 
regulate hormone production and secretion in the pituitary gland, 
thyroid gland, gastrointestinal tract, and pancreas, as well as 
endothelium-independent vasodilatation. It has been found to 
stimulate the secretion ofNPY and catecholamines (May and Braas, 
1995). 
The supply of PACAP in human skin is scant, but it occurs in 
blister fluid from inflamed skin (Wallengren j, Wang Z, Hakanson 
R, unpublished observations). In human skin PACAP induces a 
slowly developing erythema resembling that induced by CGRP 
(Wallengrenj, Hakanson R, unpublished observations). In the skin 
of the rat, PACAP-positive nerve fibers are found as free nerve 
endings near hair follicles (Wallengren j, Sundler F, unpublished 
observations), a distribution similar to that of VIP and CGRP 
(Wallengren et ai, 1987). PACAP can be partly eliminated (to 75()!o) 
from the nerve tibers of the rat skin by capsaicin (Wallengren j, 
Hakanson R, Sundler F, unpublished observations). From available 
information it appears that PACAP is a constituent of C-tiber 
neurons (together with SP and CGRP) and of parasympathetic 
neurons and fibers (together with VIP and sometimes with NPY). 
NPY NPY consists of 36 amino acid residues and has been found 
in neuronal elements in both brain and periphery. It was first 
isolated from bovine brain by Tatemoto and co-workers in 1982. 
Numerous NPY receptors have been identified. The binding 
properties of two of the NPY receptors (Y I and Y 2) have been 
described in some detail (Hashim and Tadepalli, 1995). 
Because many nerve cell bodies in the sympathetic ganglia have 
been found to store NPY, it has been suggested that noradrenergic 
sympathetic neurons contain NPY (Lundberg et ai, 1982). NPY is 
known to co-exist with NA in peripheral adrenergic neurons and to 
enhance various adrenergically mediated functions (Sundler ct ai, 
1986). A dense supply of NPY -immunoreactivity fibers is found in 
the respiratory tract, heart, gut, pancreas, and the urogenital tract 
(Sundler et ai, 1986). In these vascular beds the vasoconstrictor 
response to exogenous noradrenaline is greatly enhanced by NPY 
(Edvinsson et ai, 1984). 
In the skin, NPY fibers occur mainly in the deeper portions of 
the dermis, mostly around blood vessels and occasionally in asso­
ciation with sweat glands and hair roots (Wallengren et ai, 1987). 
We have found that concomitant intracutaneous injection of NPY 
and NA in equimolar concentrations decreases the bleaching 
induced by NA given alone (Wallengrenj, Hakanson R, Moller H, 
unpublished observations), suggesting that in the skin the two 
substances do not act synergistically. The observed cutaneous 
vasodilatation is in agreement with the paradoxical increase in 
cutaneous microvascular blood flow reported by Hashim and 
Tadepalli in 1995. The flare induced by intracutaneous injection of 
NPY is probably mediated by histamine, as NPY releases histamine 
from cutaneous mast cells (Emadi-Khiav et ai, 1995). NPY is found 
in fluid from spontaneous blisters in inflamed skin (Wallengren et ai, 
1987). NPY occurs together with NA in sympathetic fibers and 
together with VIP in a subpopulation of parasympathetic fibers. If 
NPY participates in the neurogenic inflammation in the skin, it 
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probably does so as a transmitter released from sympathetic nerve 
fibers together with NA. 
Somatostatin Somatostatin consists of 14 or 28 amino acid 
residues. It was first discovered by Brazeau and colleagues in 1973 
in hypothalamus. Specific receptors for somatostatin are expressed 
on normal and activated monocytes, and on lymphocytes, but not 
on granulocytes and red blood cells (Hiruma et ai, 1990). 
Somatostatin was subsequently demonstrated in the gastrointes­
tinal tract, and it was shown to be a highly potent inhibitor of 
peptide hormone release and cell proliferation (Brazeau et ai, 1973). 
Somatostatin is localized to neurons in the spinal ganglia (10% of 
the nerve cell bodies are somatostatin-immunoreactive) and to 
nerve fibers in the dorsal horn of the spinal cord. In the skin 
somatostatin occurs at small concentrations and with a distribution 
similar to that of SP Oohansson and Vaalasti, 1987). In normal 
human skin, the concentration of somatostatin is so low that it 
cannot be detected by immunostaining (Wallengren et ai, 1987). 
Intracutaneous injection of somatostatin induces flare and wheal 
that are fainter than that induced by SP. The two pep tides given in 
equimolar doses act synergistically producing a greater flare re­
sponse together than either of them does alone. Somatostatin is 
found in blister fluid from inflamed skin (Wallengren et ai, 1987), 
which suggests that it functions as an inflammatory mediator. 
CELL-DERIVED VASOACTIVE PEPTIDES AND 
MOLECULES 
Nitric Oxide (NO) Furchgott and Zawadzki reported in 1980 
that endothelial cells are required for the acetylcholine-evoked 
relaxation of arterial smooth muscle. Acetylcholine acting on 
muscarinic receptors was shown to release a substance, which they 
called endothelium-derived relaxing factor. In 1982 Palmer and 
co-workers showed this substance to be nitric oxide, a short-lived 
free radical (for a review see Snyder, 1992). Nitric oxide appears to 
subserve diverse types of communication. One pathway is as a 
second messenger acting within the cell or neuron in which it is 
produced. Another pathway is a cell to cell signaling, possibly 
involving N-methyl-D-aspartate type of glutamate receptors 
(Itzhak, 1994). 
The most important stimulus controlling endothelial NO synthe­
sis under physiologic conditions is probably mechanical, i.e., the 
pulses of the blood flow. Endothelial cells possess receptors for 
vasodilators including acetylcholine, SP, CGRP, adenosine diphos­
phate, and bradykinin. Occupation of these receptors stimulates the 
formation of NO (Bull et ai, 1996). Following its induction, the 
activity of NO synthase first increases and then decreases again over 
a period of hours or days, one factor of importance in the activity 
decline being irreversible feedback inhibition of NO synthase by 
NO itself. 
NO has also been implicated as a neuro-mediator in the periph­
eral nervous system, acting as a non adrenergic non cholinergic 
transmitter. Conventional neurotransmitters are stored in synaptic 
vesicles and are released by exocytosis upon stimulation. Neuronal 
NO, however, is synthesized on demand in the neuronal cytoplasm 
and diffuses freely across the cell membrane (Snyder, 1992). There 
have been reports of the co-existence of NO synthase and neu­
ropeptides both in C-fibers and parasympathetic fibers (Snyder, 
1992). 
NO is also synthesized in platelets and immune cells. Excessive 
production of NO in septicemia causes harmful hypotension by its 
action on the cardiovascular and immune system. Nitroglycerin, 
used by physicians for nearly a century to dilate blood vessels and 
lower blood pressure, has been shown to generate NO. 
Endothelins (ET) Pep tides produced by endothelial cells were 
isolated by Yangisawa and colleagues in 1988 and named endothe­
lins. The endothelin system consists of endothelin-1 (ET-1), ET-2, 
and ET -3, which are synthesized by blood vessels, both in the 
endothelial and smooth muscle cells. Two mammalian ET receptor 
isoforms have been cloned: ETA receptors, which mediate contrac­
tion of vascular smooth muscle cells; and ET B receptors of vascular 
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endothelial cells, which exert vasodilatory effects via release of NO 
and prostacyclin (Schiffrin, 1995). 
The endothelins constitute a family of vasoconstrictor pep tides 
that may also induce vascular hypertrophy (Yanagisawa ef ai, 1988). 
Through these two mechanisms, the endothelins are thought to 
participate in the pathogenesis of hypertension (Schiffrin, 1995). In 
many diseases associated with tissue hypoxia or ischemia, and in 
diseases involving vasoconstriction, the circulating levels of endo­
the lin are higher than in healthy control subjects (Brain ef ai, 1989). 
Upon infusion, ET -1 reduces the blood flow in the forearm of 
human volunteers, and local administration constricts dorsal hand 
veins (Brain et ai, 1989). Intradermal injection of ET-1 into human 
skin has been shown to reduce cutaneous blood flow. Immuno­
staining for ET -1 was observed in all cutaneous blood vessels of 
normal human skin, including the blood vessels of the dermal 
papillae as well as hair follicles and sweat glands in the dermis (Bull 
et ai, 1991). Because of its prolonged vasoconstrictor effect it has 
been suggested that ET -1 may modulate the vasospasmic episodes 
involved in Raynaud's phenomenon. 
Bradykinin Bradykinin consists of nine amino acid residues and 
belongs to the kinin family (Regoli and Barabe, 1980). There is 
more than one type of bradykinin receptor; Bl and B2 subtypes are 
recognized, although the effects mediated by these receptors are 
very similar. 
The hypotensive action of kinins was first discovered by two 
French surgeons, Abelous and Bardier, in 1909. Bradykinin was 
purified in 1956 by Andrade and Roch e Silva. It exists in the 
circulation at very low concentrations. The precursors of bradyki­
nin, kallikreins, and pre-kallikreins are released from exocrine 
glands (pancreas, kidney, intestine, salivary, and sweat glands) upon 
stimulation by the autonomic nervous system (for review see 
Regoli and Barabe, 1980). Bradykinin is a powerful stimulant of 
C-fibers and induces triple response upon intradermal injection 
(Greaves and Shuster, 1967). The intensity of the response to 
bradykinin varies from one skin region to another and diminishes 
with age. The flare response is triggered by axon reflexes and the 
release of mast-cell histamine (Wallengren and Hakanson, 1992). 
Repeated injection of bradykinin induces tachyphylaxis, which is 
reversed 8 wk after the last injection of bradykinin (Wallengren and 
Hakanson, 1992). The wheal induced by bradykinin cannot be 
inhibited by a non-peptide neurokinin!, (NK1) receptor antagonist, 
which effectively inhibits SP- and NKA-induced weal (Wilsoncroft 
ef ai, 1994). 
Prostaglandins In the 1 960s Bergstrom and Samuels son isolated 
two prostaglandins (PGE2 and PGF2cJ and determined their 20-
carbon fatty acid structure. Additionally three prostaglandins, all 
with the same carbon skeleton (prostanoic acid), were defined later. 
Five main prostanoid receptors have been defined, one each for the 
natural prostaglandins (EP-receptor for PGE2, DP-receptor for 
PGD2, and IP-receptor for PGI2). 
Prostaglandins are generated de novo from arachidonic acid by 
cyclo-oxygenase activity. PGE2 is produced mainly by macrophages 
and neutrophils, PGD2 mainly by mast cells and basophils, and PGI2 
by the endothelium. The prostaglandins differ in their actions. PGI2 
is a vasodilator that acts synergistically with NO in relaxing vascular 
smooth muscle; it also inhibits platelet aggregation. PGE2 relaxes 
smooth muscle and acts as a bronchodilatator and enhancer of 
cutaneous permeability. Intracutaneous injection of PGE2 induces 
an indurated erythema with pseudopodia, a reaction resembling 
that of CGRP but of shorter duration. The PGE2 response is partly 
(to 30'%) dependent on axon reflexes and release of mast-cell 
histamine (Wallengren and Hakanson, 1992). The PGE2-induced 
vasodilatation in the skin potentiates histamine-, serotonin-, and 
bradykinin-evoked edema and itch (Williams and Morley, 1973). 
Indomethacin blockade of prostaglandin synthesis inhibits the flare 
response to SP by approximately 40°/c, and inhibits the flare response 
to bradykinin by 70'X, (Wallengren and Hakanson, 1992b). These 
findings suggest that prostaglandins interfere with the neurogenic 
mechanisms responsible for inflammation in the skin. Nonsteroidal 
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anti-inflammatory drugs have not proved to be effective in the 
treatment of skin diseases (Greaves, 1987). 
Histamine Most of the early studies on the biologic action of 
histamine were performed by Lewis in the 1920s and Dale in the 
1930s. Specific histamine receptors, of three types (Hi
' 
H2, and 
H3)' have been defined. H1-receptors are found in human airways 
and skin, H2-receptors in the gastrointestinal tract, and H3-recep­
tors are mainly associated with neural tissue at pre-synaptic sites. 
Histamine is 2-(4-imidazolyl)-ethylamine, formed from histidine 
by histidine decarboxylase. At the cellular level, it occurs mainly in 
mast cells and basophils. Non-mast-cell histamine occurs mainly in 
the brain where it may serve as transmitter in histaminergic 
neurons. Histamine was the first substance found to induce the 
triple response, as demonstrated by Lewis in 1927. The histamine­
evoked flare reaction is almost abolished by local anesthetics 
(Wallengren and Hakanson, 1987) (Fig 2e). The part played by 
histamine in neurogenic inflammation is still a matter of debate. It 
is generally agreed that histamine is released in response to noxious 
stimulus. The crucial question is whether histamine participates in 
the progressive spread of the flare, by activating sensory nerve 
endings to release neurogenic mediators (e.g., tachykinins) fol­
lowed by further histamine release (reinforcement). This cascade of 
responses has been termed the 'axon response' (Lembeck and 
Holzer, 1979), to distinguish it from the classic 'axon reflex.' The 
latter concept implies that the spread of the flare is mainly 
dependent on the anti-dromic passage of impulses. That the flare is 
limited by the extent of the collateral network was initially 
demonstrated by Bayliss (for review see Foreman and Jordan, 
1983). The question of the function of histamine and its interaction 
with C-fibers in neurogenic inflammation has been throughly 
investigated using capsaicin as an experimental tool. 
CAPSAICIN 
Capsaicin is the active agent in hot pepper of the genus capsicum. 
Chemically, capsaicin is trans-8-methyl-N-vanillyl-6-nonenamide. 
It was introduced to pharmacology by Jancso and collaborators in 
the 1960s in order to elucidate the function of sensory nerve 
endings in neurogenic inflammation. Capsaicin produces irrevers­
ible damage to C-fibers in rats, only if administered neonatally. 
Systemic administration of capsaicin to adult animals may cause 
transient depletion of SP from small sensory neurons and their 
terminals (C-fibers), which results in bronchospasm and skin 
irritation, but the nerves do not degenerate (for review see 
Fitzgerald, 1983). Applied locally to the sciatic nerve, capsaicin 
blocks axonal transport of peptides. The effect is specific to sensory 
C-fibers and is not due to local damage of those fibers because they 
are still capable of conducting action potentials. A single application 
of capsaicin causes a flare and wheal reaction. Repeated topical 
administration of capsaicin in human skin induces tachyphylaxis and 
abolishes the axon reflex to a number of noxious agents. The axon 
reflex recovers after 8 wk, indicating that there are no chronic 
effects (Wallengren and Hakanson, 1992). 
The flare and weal responses induced by intracutaneous injection 
of capsaicin can be inhibited by local anesthetics and indomethacin, 
but not by compound 48/80 or histamine Hcreceptor antagonist 
(Wallengren and Hakanson, 1992b) (Fig 3). This favors the axon 
reflex theory, which states that histamine is a primary, but not a 
secondary, mediator of neurogenic inflammation. 
CONCLUSIONS 
Blood vessels in the skin are affected by nervous control mecha­
nisms and by locally derived vasoactive substances, the pathway 
involved probably differing from one skin region to another. 
Dermal blood vessels of the extremities are controlled by the 
sympathetic nervous system, whereas those of the head and upper 
thorax (the 'blush area') are predominantly controlled by the 
parasympathetic nervous system and by circulating vasoactive 
agents. Several endogenous systems intervene and interact in a 
complex manner. All peptides in the C-fibers are probably released 
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concomitantly when the nerves are stimulated. The actions and 
interactions of the different agents discussed above are schemati­
cally illustrated in Fig 4. 
Endothelin receptor antagonists have been used to treat hyper­
tension (Schiffrin, 1995). NO synthase inhibitors (such as L-N 
monomethyl arginine) have been used in the treatment of hypo­
tensive shock. 
The special features of the dermal circulation are important in the 
regulation of body temperature. In some pathologic conditions, 
peptidergic drugs may be useful. CGRP, for instance, has been 
given intravenously to patients with Raynaud's phenomenon, in 
order to cause vasodilatation (Bunker et aI, 1989). 
High concentrations of neuropeptides are found in spontaneous 
bullae in pathogenetically different inflammatory skin diseases 
(Wallengren et aI, 1987). This emphasizes the importance of 
sensory and autonomic nerves in the inflammatory process. Capsa­
icin is a drug that can prevent or modify inflammation in the skin by 
depleting C fibers of their neurotransmitters. In addition, capsaicin 
has been used therapeutically to alleviate pain and itch (Bernstein, 
1992). 
I am grateful to Professor Rolf Hakallsoll for stimulatillg discussiolls alld valuable 
comments. 
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